NASDAQ:LHDX Lucira Health - LHDX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lucira Health, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.39 -0.02 (-4.85%) (As of 02/1/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.36▼$0.4150-Day Range$0.11▼$0.6052-Week Range$0.11▼$5.67Volume2.03 million shsAverage Volume14.96 million shsMarket Capitalization$15.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Lucira Health MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy4.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingSelling Shares$20,945 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.49) to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 starsMedical Sector686th out of 1,053 stocksDiagnostic Substances Industry9th out of 17 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Lucira Health. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.04% of the float of Lucira Health has been sold short.Short Interest Ratio / Days to CoverLucira Health has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lucira Health has recently increased by 2,165.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLucira Health does not currently pay a dividend.Dividend GrowthLucira Health does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LHDX. Previous Next 3.0 News and Social Media Coverage News SentimentLucira Health has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Lucira Health this week, compared to 1 article on an average week.Search Interest20 people have searched for LHDX on MarketBeat in the last 30 days. This is an increase of 900% compared to the previous 30 days.MarketBeat Follows4 people have added Lucira Health to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lucira Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $20,945.00 in company stock.Percentage Held by Insiders30.40% of the stock of Lucira Health is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions57.02% of the stock of Lucira Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Lucira Health are expected to grow in the coming year, from ($0.49) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lucira Health is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lucira Health is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLucira Health has a P/B Ratio of 0.08. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Lucira Health (NASDAQ:LHDX) StockLucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.Read More Receive LHDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lucira Health and its competitors with MarketBeat's FREE daily newsletter. Email Address LHDX Stock News HeadlinesFebruary 1, 2023 | finance.yahoo.com5 Big Winners as Wall Street Wraps Up Strong January GainsJanuary 24, 2023 | americanbankingnews.comReviewing Cardio Diagnostics (NASDAQ:CDIO) and Lucira Health (NASDAQ:LHDX)February 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 20, 2023 | benzinga.comThinking about buying stock in WiSA Technologies, Arrival, Marathon Digital, Lucira Health, or Hut 8 Mining?January 5, 2023 | finance.yahoo.comSESAME PARTNERS WITH LUCIRA HEALTH AS OFFICIAL TELEHEALTH PROVIDER OF LAB-QUALITY TEST-TO-TREAT PROGRAMJanuary 4, 2023 | nasdaq.comLucira Health Slide ContinuesJanuary 4, 2023 | finance.yahoo.comAs EU works to coordinate response to China’s COVID wave, Beijing and airlines are unhappyJanuary 4, 2023 | finance.yahoo.comLucira Health Launches Lucira Connect, a Free Test-to-Treat Telehealth Service for Covid-19 or Flu in CanadaFebruary 2, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 3, 2023 | benzinga.comWhy Lucira Health Shares Are Trading Higher TodayDecember 26, 2022 | benzinga.comLooking Into Lucira Health's Return On Capital EmployedNovember 22, 2022 | finance.yahoo.comLucira Health Announces FDA Authorization of Combination COVID-19 & Flu Test at Point-of-CareNovember 17, 2022 | finance.yahoo.comLucira Health Announces National Launch of Lucira Connect Test-to-Treat ServiceNovember 15, 2022 | seekingalpha.comLucira Health, Inc. (LHDX) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | finance.yahoo.comLucira Health Announces Third Quarter 2022 Results and Provides Business UpdatesNovember 8, 2022 | finance.yahoo.comLucira Health cuts quarter of workforce as it awaits FDA decision on combo Covid-flu testNovember 1, 2022 | finance.yahoo.comLucira Health to Announce Third Quarter 2022 Financial ResultsSeptember 29, 2022 | finance.yahoo.comLucira Health Reports Pilot Study Interim Results for Chlamydia and Gonorrhea AssaysSeptember 8, 2022 | bizjournals.comHow Covid set up this East Bay company for a possible flu test (and more)September 8, 2022 | finance.yahoo.comHow Covid set up Lucira Health for a possible flu test (and more)September 7, 2022 | finance.yahoo.comLucira Health to Participate in LifeSci Partners HealthTech SymposiumAugust 31, 2022 | finance.yahoo.comLucira CEO: COVID-19 ‘catalyzed the growth of the company’August 23, 2022 | finance.yahoo.comLucira Health to Present at the Inaugural Gilmartin Group Emerging Growth Company ShowcaseAugust 16, 2022 | nasdaq.comShareholders in Lucira Health (NASDAQ:LHDX) are in the red if they invested a year agoAugust 16, 2022 | finance.yahoo.comLucira Health Announces Second Quarter 2022 Results and Provides Business UpdatesAugust 16, 2022 | fool.comLucira Health, Inc. (LHDX) Q2 2022 Earnings Call TranscriptAugust 13, 2022 | finance.yahoo.comA Lucira Health, Inc. (NASDAQ:LHDX) insider increased their holdings by 11% last yearSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LHDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lucira Health and its competitors with MarketBeat's FREE daily newsletter. Email Address LHDX Company Calendar Last Earnings11/14/2022Today2/01/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LHDX CUSIPN/A CIK1652724 Webwww.lucirahealth.com Phone510-350-8071FaxN/AEmployees114Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,830,000.00 Net Margins-67.54% Pretax Margin-67.53% Return on Equity-13.55% Return on Assets-8.47% Debt Debt-to-Equity Ratio0.48 Current Ratio1.46 Quick Ratio0.79 Sales & Book Value Annual Sales$93.06 million Price / Sales0.17 Cash FlowN/A Price / Cash FlowN/A Book Value$4.81 per share Price / Book0.08Miscellaneous Outstanding Shares40,110,000Free Float27,914,000Market Cap$15.73 million OptionableNot Optionable Beta2.07 Key ExecutivesMr. Erik T. Engelson (Age 62)Pres, CEO & Director Comp: $1.05MMr. Kevin Walter Collins (Age 45)Chief Revenue Officer Comp: $740.75kMr. Ghazi Kashmolah (Age 61)Chief Quality Officer & Exec. VP of Regulatory Affairs Comp: $603.47kMr. Richard Clavano NaridoChief Financial OfficerMr. Tony Allen (Age 59)Chief Operations Officer Greg ChodaczekInvestor RelationsDr. Nadine Greiner Ph.D.Chief HR OfficerMore ExecutivesKey CompetitorsVirax Biolabs GroupNASDAQ:VRAXNavidea BiopharmaceuticalsNYSE:NAVBARCA biopharmaNASDAQ:ABIOBiomericaNASDAQ:BMRATrinity BiotechNASDAQ:TRIBView All CompetitorsInsiders & InstitutionsAnthony Joseph AllenSold 4,263 sharesTotal: $682.08 ($0.16/share)Ghazi KashmolahSold 7,537 sharesTotal: $3,165.54 ($0.42/share)Kevin Walter CollinsSold 9,666 sharesTotal: $4,059.72 ($0.42/share)Anthony Joseph AllenSold 34,429 sharesTotal: $11,361.57 ($0.33/share)Ghazi KashmolahSold 4,790 sharesTotal: $1,676.50 ($0.35/share)View All Insider TransactionsView All Institutional Transactions LHDX Stock - Frequently Asked Questions Should I buy or sell Lucira Health stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Lucira Health in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" LHDX shares. View LHDX analyst ratings or view top-rated stocks. How have LHDX shares performed in 2023? Lucira Health's stock was trading at $0.1111 on January 1st, 2023. Since then, LHDX shares have increased by 253.0% and is now trading at $0.3922. View the best growth stocks for 2023 here. Are investors shorting Lucira Health? Lucira Health saw a increase in short interest in January. As of January 15th, there was short interest totaling 1,210,000 shares, an increase of 2,165.9% from the December 31st total of 53,400 shares. Based on an average trading volume of 4,880,000 shares, the short-interest ratio is presently 0.2 days. Currently, 4.0% of the company's shares are sold short. View Lucira Health's Short Interest. When is Lucira Health's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our LHDX earnings forecast. How were Lucira Health's earnings last quarter? Lucira Health, Inc. (NASDAQ:LHDX) posted its quarterly earnings results on Monday, November, 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.38). The company earned $34.39 million during the quarter, compared to the consensus estimate of $33.30 million. Lucira Health had a negative trailing twelve-month return on equity of 13.55% and a negative net margin of 67.54%. When did Lucira Health IPO? (LHDX) raised $125 million in an initial public offering on Friday, February 5th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. BofA Securities, William Blair and LifeSci Capital acted as the underwriters for the IPO. What is Lucira Health's stock symbol? Lucira Health trades on the NASDAQ under the ticker symbol "LHDX." Who are Lucira Health's major shareholders? Lucira Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anthony Joseph Allen, Dan George, Debkishore Mitra, Epiq Capital Group, Llc, Erik T Engelson, Ghazi Kashmolah, Kevin Walter Collins and Tamanna Prashar. View institutional ownership trends. How do I buy shares of Lucira Health? Shares of LHDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Lucira Health's stock price today? One share of LHDX stock can currently be purchased for approximately $0.39. How much money does Lucira Health make? Lucira Health (NASDAQ:LHDX) has a market capitalization of $15.73 million and generates $93.06 million in revenue each year. The company earns $-64,830,000.00 in net income (profit) each year or ($3.58) on an earnings per share basis. How many employees does Lucira Health have? The company employs 114 workers across the globe. How can I contact Lucira Health? Lucira Health's mailing address is 1412 62ND STREET, EMERYVILLE CA, 94608. The official website for the company is www.lucirahealth.com. The company can be reached via phone at 510-350-8071. This page (NASDAQ:LHDX) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.